HEADER TRANSFERASE 31-OCT-05 2C5P
OBSLTE 09-JUN-09 2C5P 2WEV
TITLE DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE
TITLE 2 CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2;
COMPND 3 CHAIN: A, C;
COMPND 4 SYNONYM: CYCLIN-DEPENDENT KINASE 2, P33 PROTEIN KINASE;
COMPND 5 EC: 2.7.1.37;
COMPND 6 ENGINEERED: YES;
COMPND 7 MOL_ID: 2;
COMPND 8 MOLECULE: CYCLIN A2;
COMPND 9 CHAIN: B, D;
COMPND 10 SYNONYM: CYCLIN A;
COMPND 11 ENGINEERED: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 ORGANISM_TAXID: 9606;
SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA;
SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108;
SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS;
SOURCE 8 MOL_ID: 2;
SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 10 ORGANISM_COMMON: HUMAN;
SOURCE 11 ORGANISM_TAXID: 9606;
SOURCE 12 EXPRESSION_SYSTEM: ESCHERICHIA COLI;
SOURCE 13 EXPRESSION_SYSTEM_TAXID: 562
KEYWDS DIFFERENTIAL INHIBITION, TRANSFERASE, CDK2, ATP-BINDING,
KEYWDS 2 CELL CYCLE, CELL DIVISION, POLYMORPHISM, PHOSPHORYLATION,
KEYWDS 3 NUCLEOTIDE-BINDING, SERINE/THREONINE-PROTEIN, KINASE,
KEYWDS 4 MITOSIS, CYCLIN
EXPDTA X-RAY DIFFRACTION
AUTHOR G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE,D.GIBSON,
AUTHOR 2 M.MEZNA,M.THOMAS,G.WOOD,S.WANG,M.D.WALKINSHAW,P.M.FISCHER
REVDAT 3 09-JUN-09 2C5P 1 OBSLTE
REVDAT 2 24-FEB-09 2C5P 1 VERSN
REVDAT 1 01-MAR-06 2C5P 0
JRNL AUTH G.KONTOPIDIS,C.MCINNES,S.R.PANDALANENI,I.MCNAE,
JRNL AUTH 2 D.GIBSON,M.MEZNA,M.THOMAS,G.WOOD,S.WANG,
JRNL AUTH 3 M.D.WALKINSHAW,P.M.FISCHER
JRNL TITL DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND
JRNL TITL 2 INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN.
JRNL REF CHEM.BIOL. V. 13 201 2006
JRNL REFN ISSN 1074-5521
JRNL PMID 16492568
JRNL DOI 10.1016/J.CHEMBIOL.2005.11.011
REMARK 2
REMARK 2 RESOLUTION. 2.3 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : REFMAC 5.0
REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON
REMARK 3
REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 12.00
REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL
REMARK 3 COMPLETENESS FOR RANGE (%) : 96.1
REMARK 3 NUMBER OF REFLECTIONS : 54909
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING + TEST SET) : 0.181
REMARK 3 R VALUE (WORKING SET) : 0.178
REMARK 3 FREE R VALUE : 0.242
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000
REMARK 3 FREE R VALUE TEST SET COUNT : 2911
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : 20
REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.30
REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.36
REMARK 3 REFLECTION IN BIN (WORKING SET) : 2919
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL
REMARK 3 BIN R VALUE (WORKING SET) : 0.1670
REMARK 3 BIN FREE R VALUE SET COUNT : 126
REMARK 3 BIN FREE R VALUE : 0.2500
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 8932
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 92
REMARK 3 SOLVENT ATOMS : 655
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : NULL
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 20.47
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : 1.74000
REMARK 3 B22 (A**2) : -0.92000
REMARK 3 B33 (A**2) : -0.82000
REMARK 3 B12 (A**2) : 0.00000
REMARK 3 B13 (A**2) : 0.00000
REMARK 3 B23 (A**2) : 0.00000
REMARK 3
REMARK 3 ESTIMATED OVERALL COORDINATE ERROR.
REMARK 3 ESU BASED ON R VALUE (A): 0.331
REMARK 3 ESU BASED ON FREE R VALUE (A): 0.242
REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.227
REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 9.172
REMARK 3
REMARK 3 CORRELATION COEFFICIENTS.
REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.936
REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.886
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT
REMARK 3 BOND LENGTHS REFINED ATOMS (A): 9367 ; 0.015 ; 0.022
REMARK 3 BOND LENGTHS OTHERS (A): 8551 ; 0.000 ; 0.020
REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 12752 ; 1.786 ; 1.991
REMARK 3 BOND ANGLES OTHERS (DEGREES): 20037 ; 1.489 ; 3.000
REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 1110 ; 6.736 ; 3.000
REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): NULL ; NULL ; NULL
REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 1768 ;22.074 ;15.000
REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): NULL ; NULL ; NULL
REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 1439 ; 0.120 ; 0.200
REMARK 3 GENERAL PLANES REFINED ATOMS (A): 10076 ; 0.008 ; 0.020
REMARK 3 GENERAL PLANES OTHERS (A): 1812 ; 0.003 ; 0.020
REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 2547 ; 0.287 ; 0.300
REMARK 3 NON-BONDED CONTACTS OTHERS (A): 8894 ; 0.255 ; 0.300
REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL
REMARK 3 NON-BONDED TORSION OTHERS (A): 2 ; 0.112 ; 0.500
REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 1180 ; 0.236 ; 0.500
REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL
REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL
REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 22 ; 0.276 ; 0.300
REMARK 3 SYMMETRY VDW OTHERS (A): 48 ; 0.272 ; 0.300
REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 30 ; 0.324 ; 0.500
REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL
REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT
REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 5567 ; 1.825 ; 1.500
REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 9053 ; 3.173 ; 2.000
REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 3800 ; 4.569 ; 3.000
REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 3661 ; 7.359 ; 4.500
REMARK 3
REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT
REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL
REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL
REMARK 3
REMARK 3 NCS RESTRAINTS STATISTICS
REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL
REMARK 3
REMARK 3 TLS DETAILS
REMARK 3 NUMBER OF TLS GROUPS : NULL
REMARK 3
REMARK 3 BULK SOLVENT MODELLING.
REMARK 3 METHOD USED : BABINET MODEL WITH MASK
REMARK 3 PARAMETERS FOR MASK CALCULATION
REMARK 3 VDW PROBE RADIUS : 1.40
REMARK 3 ION PROBE RADIUS : 0.80
REMARK 3 SHRINKAGE RADIUS : 0.80
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE
REMARK 3 RIDING POSITIONS.
REMARK 4
REMARK 4 2C5P COMPLIES WITH FORMAT V. 3.15, 01-DEC-08
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 31-OCT-05.
REMARK 100 THE PDBE ID CODE IS EBI-26225.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 04-SEP-02
REMARK 200 TEMPERATURE (KELVIN) : 100.0
REMARK 200 PH : 7.80
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : ESRF
REMARK 200 BEAMLINE : ID14-1
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 0.933
REMARK 200 MONOCHROMATOR : NULL
REMARK 200 OPTICS : MIRRORS
REMARK 200
REMARK 200 DETECTOR TYPE : CCD
REMARK 200 DETECTOR MANUFACTURER : ADSC
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM
REMARK 200 DATA SCALING SOFTWARE : CCP4 (SCALA)
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 60655
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300
REMARK 200 RESOLUTION RANGE LOW (A) : 40.000
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 96.4
REMARK 200 DATA REDUNDANCY : 4.100
REMARK 200 R MERGE (I) : 0.09000
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 15.7000
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.30
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.42
REMARK 200 COMPLETENESS FOR SHELL (%) : 80.4
REMARK 200 DATA REDUNDANCY IN SHELL : NULL
REMARK 200 R MERGE FOR SHELL (I) : 0.28000
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : 7.200
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: MOLREP
REMARK 200 STARTING MODEL: PDB ENTRY 1OL1
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 50.02
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.48
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: NULL
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X+1/2,-Y,Z+1/2
REMARK 290 3555 -X,Y+1/2,-Z+1/2
REMARK 290 4555 X+1/2,-Y+1/2,-Z
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 37.26150
REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 79.23100
REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 56.92200
REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 79.23100
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 37.26150
REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 56.92200
REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1, 2
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 GENERATING THE BIOMOLECULE
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC
REMARK 350 SOFTWARE USED: PQS
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 350 BIOMOLECULE: 2
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC
REMARK 350 SOFTWARE USED: PQS
REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 400
REMARK 400 COMPOUND
REMARK 400 INVOLVED IN THE CONTROL OF THE CELL CYCLE.
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 ARG A 297
REMARK 465 LEU A 298
REMARK 465 ASN B 173
REMARK 465 GLU B 174
REMARK 465 LEU C 298
REMARK 465 ASN D 173
REMARK 465 GLU D 174
REMARK 470
REMARK 470 MISSING ATOM
REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER;
REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER;
REMARK 470 I=INSERTION CODE):
REMARK 470 M RES CSSEQI ATOMS
REMARK 470 LEU A 296 O
REMARK 470 LEU B 432 O
REMARK 470 ARG C 297 CA C O CB CG CD NE CZ NH1 NH2
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT
REMARK 500
REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT.
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE
REMARK 500 OE2 GLU A 42 - CG2 VAL B 275 2.12
REMARK 500 OH TYR A 77 - O HOH A 2055 2.09
REMARK 500 OD2 ASP A 127 - O HOH A 2071 2.18
REMARK 500 OH TYR A 159 - O HOH A 2089 2.06
REMARK 500 OE2 GLU A 224 - OG1 THR A 231 2.13
REMARK 500 CG1 VAL A 226 - O HOH A 2120 2.18
REMARK 500 OD2 ASP A 247 - O HOH A 2132 2.18
REMARK 500 ND1 HIS A 268 - O HOH A 2144 2.12
REMARK 500 CE1 HIS A 268 - O HOH A 2144 2.02
REMARK 500 O LYS B 192 - O HOH B 2038 1.91
REMARK 500 NE2 GLN B 317 - O HOH B 2104 2.15
REMARK 500 O GLY B 420 - N SER B 422 2.10
REMARK 500 O SER B 422 - O HOH B 2155 1.95
REMARK 500 O ASP C 38 - N GLU C 40 1.78
REMARK 500 OD1 ASP C 38 - O HOH C 2023 2.04
REMARK 500 OG1 THR C 218 - O HOH C 2115 2.09
REMARK 500 NZ LYS C 278 - O ASP D 177 2.19
REMARK 500 CE1 HIS D 296 - O HOH D 2096 1.91
REMARK 500 NE2 HIS D 296 - O HOH D 2096 2.14
REMARK 500 CB ASN D 312 - O HOH D 2103 2.02
REMARK 500 CG ASN D 312 - O HOH D 2103 2.06
REMARK 500 OD1 ASN D 312 - O HOH D 2103 1.89
REMARK 500 NZ LYS D 349 - O HOH D 2117 2.14
REMARK 500 O HOH A 2091 - O HOH A 2093 1.98
REMARK 500 O HOH B 2020 - O HOH B 2127 1.96
REMARK 500 O HOH B 2078 - O HOH A 2089 2.09
REMARK 500 O HOH D 2067 - O HOH D 2072 2.10
REMARK 500 O HOH D 2087 - O HOH D 2089 2.19
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CLOSE CONTACTS
REMARK 500
REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC
REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15
REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A
REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375
REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE
REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS.
REMARK 500
REMARK 500 DISTANCE CUTOFF:
REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS
REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS
REMARK 500
REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE
REMARK 500
REMARK 500 ND2 ASN B 431 OD1 ASP C 210 2664 1.87
REMARK 500 CB ASP C 210 O HOH B 2160 2665 2.14
REMARK 500 OD1 ASP C 210 ND2 ASN B 431 2665 1.87
REMARK 500 O HOH B 2160 CB ASP C 210 2664 2.14
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: COVALENT BOND ANGLES
REMARK 500
REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES
REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE
REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1)
REMARK 500
REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999
REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996
REMARK 500
REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3
REMARK 500 ASP A 145 CB - CG - OD2 ANGL. DEV. = 6.3 DEGREES
REMARK 500 VAL A 230 CB - CA - C ANGL. DEV. = -12.3 DEGREES
REMARK 500 ASP B 216 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES
REMARK 500 ASP B 343 CB - CG - OD2 ANGL. DEV. = 5.8 DEGREES
REMARK 500 ASP B 345 CB - CG - OD2 ANGL. DEV. = 9.8 DEGREES
REMARK 500 VAL C 64 CB - CA - C ANGL. DEV. = -13.0 DEGREES
REMARK 500 ASP C 235 CB - CG - OD2 ANGL. DEV. = 6.6 DEGREES
REMARK 500 ARG C 274 NE - CZ - NH2 ANGL. DEV. = -3.6 DEGREES
REMARK 500 ASP D 205 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES
REMARK 500 ASP D 284 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES
REMARK 500 ASP D 305 CB - CG - OD2 ANGL. DEV. = 5.4 DEGREES
REMARK 500 ASP D 343 CB - CG - OD2 ANGL. DEV. = 6.4 DEGREES
REMARK 500 CYS D 390 CA - CB - SG ANGL. DEV. = -6.9 DEGREES
REMARK 500 ASP D 393 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 ARG A 36 109.99 -58.01
REMARK 500 LEU A 96 -66.06 96.49
REMARK 500 ARG A 126 -15.96 84.27
REMARK 500 ASP A 145 86.58 59.31
REMARK 500 THR A 165 129.90 122.57
REMARK 500 SER A 207 -179.42 -171.00
REMARK 500 THR A 290 -167.39 -128.25
REMARK 500 PRO B 176 -1.26 -38.64
REMARK 500 PHE B 304 13.80 55.24
REMARK 500 ASP B 345 -69.31 22.90
REMARK 500 TRP B 372 109.04 -34.12
REMARK 500 VAL B 421 -48.12 -9.97
REMARK 500 LEU B 424 141.57 -33.47
REMARK 500 GLU C 8 142.56 179.20
REMARK 500 ASP C 38 78.29 -45.94
REMARK 500 THR C 39 35.16 -20.10
REMARK 500 THR C 41 -121.44 -84.25
REMARK 500 ASN C 74 23.57 -144.07
REMARK 500 LEU C 96 -55.66 92.30
REMARK 500 ARG C 126 -14.21 81.87
REMARK 500 ASP C 127 48.02 -145.65
REMARK 500 ASP C 145 79.91 63.12
REMARK 500 HIS C 161 87.74 15.54
REMARK 500 ARG C 199 7.95 82.45
REMARK 500 THR C 290 -167.56 -125.08
REMARK 500 THR D 303 46.32 38.49
REMARK 500 GLU D 374 -51.36 -27.16
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS
REMARK 500
REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH
REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED
REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND
REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES.
REMARK 500 MODEL OMEGA
REMARK 500 ALA B 344 ASP B 345 148.59
REMARK 500 ASP B 345 PRO B 346 144.56
REMARK 500 GLY D 198 TYR D 199 -143.49
REMARK 500 ALA D 344 ASP D 345 -149.47
REMARK 500 ASP D 345 PRO D 346 137.54
REMARK 500
REMARK 500 REMARK: NULL
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: CHIRAL CENTERS
REMARK 500
REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL
REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY
REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16)
REMARK 500
REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS
REMARK 500 TYR B 271 22.8 L L OUTSIDE RANGE
REMARK 500 ASP B 345 24.2 L L OUTSIDE RANGE
REMARK 500
REMARK 500 REMARK: NULL
REMARK 525
REMARK 525 SOLVENT
REMARK 525
REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT
REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST
REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT
REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE
REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER;
REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE
REMARK 525 NUMBER; I=INSERTION CODE):
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CK7 A1297
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CK7 C1298
REMARK 900
REMARK 900 RELATED ENTRIES
REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE INHIBITOR STAUROSPORINE
REMARK 900 RELATED ID: 1B38 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1B39 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED
REMARK 900 ON THR 160
REMARK 900 RELATED ID: 1BUH RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE
REMARK 900 COMPLEX WITHCELL CYCLE-REGULATORY PROTEIN
REMARK 900 CKSHS1
REMARK 900 RELATED ID: 1CKP RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE INHIBITOR PURVALANOL B
REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2
REMARK 900 (CDK2) IN COMPLEX WITH 4-[3-
REMARK 900 HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE
REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE INHIBITOR HYMENIALDISINE
REMARK 900 RELATED ID: 1E1V RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE INHIBITOR NU2058
REMARK 900 RELATED ID: 1E1X RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE INHIBITOR NU6027
REMARK 900 RELATED ID: 1E9H RELATED DB: PDB
REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN
REMARK 900 A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-
REMARK 900 SULPHONATE BOUND
REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS
REMARK 900 CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDANT
REMARK 900 KINASE 2
REMARK 900 RELATED ID: 1FIN RELATED DB: PDB
REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX
REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED
REMARK 900 PHOSPHATASE (KAP) INCOMPLEX WITH PHOSPHO-CDK2
REMARK 900 RELATED ID: 1FVT RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2
REMARK 900 (CDK2) INCOMPLEX WITH AN OXINDOLE INHIBITOR
REMARK 900 RELATED ID: 1FVV RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX
REMARK 900 WITH AN OXINDOLEINHIBITOR
REMARK 900 RELATED ID: 1G5S RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT
REMARK 900 KINASE 2 (CDK2)IN COMPLEX WITH THE
REMARK 900 INHIBITOR H717
REMARK 900 RELATED ID: 1GIH RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE CDK4INHIBITOR
REMARK 900 RELATED ID: 1GII RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE CDK4INHIBITOR
REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE CDK4INHIBITOR
REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB
REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP,
REMARK 900 NITRATE AND PEPTIDE SUBSTRATE
REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THE INHIBITOR 2-AMINO-6-(3'-METHYL-
REMARK 900 2'-OXO)BUTOXYPURINE
REMARK 900 RELATED ID: 1H00 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6
REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H01 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4
REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H07 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6
REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H08 RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4
REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
REMARK 900 RELATED ID: 1H0V RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN
REMARK 900 COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R
REMARK 900 )-PYRROLIDINO-5'-YL]METHOXYPURINE
REMARK 900 RELATED ID: 1H0W RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN
REMARK 900 COMPLEX WITH THE INHIBITOR 2-AMINO-6-[
REMARK 900 CYCLOHEX-3-ENYL]METHOXYPURINE
REMARK 900 RELATED ID: 1H1P RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
REMARK 900 RELATED ID: 1H1R RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
REMARK 900 RELATED ID: 1H1S RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
REMARK 900 RELATED ID: 1H24 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE
REMARK 900 RECRUITMENT PEPTIDE FROM E2F
REMARK 900 RELATED ID: 1H25 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE
REMARK 900 RECRUITMENT PEPTIDE FROM E2F
REMARK 900 RELATED ID: 1H26 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE
REMARK 900 RECRUITMENT PEPTIDE FROM P53
REMARK 900 RELATED ID: 1H27 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE
REMARK 900 RECRUITMENT PEPTIDE FROM P27
REMARK 900 RELATED ID: 1H28 RELATED DB: PDB
REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE
REMARK 900 RECRUITMENT PEPTIDE FROM P107
REMARK 900 RELATED ID: 1HCK RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1HCL RELATED DB: PDB
REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2
REMARK 900 RELATED ID: 1JST RELATED DB: PDB
REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND
REMARK 900 TO CYCLIN A
REMARK 900 RELATED ID: 1JSU RELATED DB: PDB
REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX
REMARK 900 RELATED ID: 1JSV RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2
REMARK 900 (CDK2) INCOMPLEX WITH 4-[(6-AMINO-4-
REMARK 900 PYRIMIDINYL)AMINO]BENZENESULFONAMIDE
REMARK 900 RELATED ID: 1JVP RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 (
REMARK 900 UNPHOSPHORYLATED) INCOMPLEX WITH PKF049-365
REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB
REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-
REMARK 900 1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]
REMARK 900 AMINO}BENZENESULFONAMIDE
REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED
REMARK 900 WITH N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO
REMARK 900 -8H-[1,3]THIAZOLO[5,4-E]INDOL-8-
REMARK 900 YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED
REMARK 900 WITH 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-
REMARK 900 BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-
REMARK 900 OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-
REMARK 900 ONE
REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED
REMARK 900 WITH 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3
REMARK 900 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-
REMARK 900 YL)BENZENESULFONAMIDE
REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB
REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED
REMARK 900 WITH 3-{[4-({[AMINO(IMINO)METHYL]
REMARK 900 AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-
REMARK 900 DIHYDRO-1H-INDOLE
REMARK 900 RELATED ID: 1OGU RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-
REMARK 900 CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE
REMARK 900 INHIBITOR
REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH A 6-
REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB
REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS
REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS
REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
REMARK 900 RELATED ID: 1OIR RELATED DB: PDB
REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS
REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS
REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
REMARK 900 RELATED ID: 1OIT RELATED DB: PDB
REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS
REMARK 900 OF CYCLIN-DEPENDENT KINASE INHIBITORS
REMARK 900 IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
REMARK 900 RELATED ID: 1OIU RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH A 6-
REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
REMARK 900 RELATED ID: 1OIY RELATED DB: PDB
REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/
REMARK 900 CYCLIN A COMPLEXED WITH A 6-
REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
REMARK 900 RELATED ID: 1OKU RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ALA-
REMARK 900 ALA-ABU-ARG-ER-LEU-ILE-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1OKV RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG-
REMARK 900 ARG-LEU-ILE-PHE-NH2
REMARK 900 RELATED ID: 1OKW RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-
REMARK 900 ARG-LEU-ASN-(M-CL-PHE)-NH2
REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT-
REMARK 900 CIT-LEU-ILE-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG-
REMARK 900 ARG-LEU-ASN-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1P2A RELATED DB: PDB
REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2
REMARK 900 (CKD2) WITH ATRISUBSTITUTED NAPHTHOSTYRIL
REMARK 900 INHIBITOR
REMARK 900 RELATED ID: 1P5E RELATED DB: PDB
REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN
REMARK 900 COMPLEX WITH THEINHIBITOR 4,5,6,7-
REMARK 900 TETRABROMOBENZOTRIAZOLE (TBS)
REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT
REMARK 900 KINASE 2COMPLEXED WITH A NUCLEOSIDE INHIBITOR
REMARK 900 RELATED ID: 1PKD RELATED DB: PDB
REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX
REMARK 900 WITH PHOSPHO-CDK2/CYCLIN A
REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB
REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT
REMARK 900 KINASE 2
REMARK 900 RELATED ID: 1PXI RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR 4-(2,5-DICHLORO-THIOPHEN-
REMARK 900 3-YL)-PYRIMIDIN-2-YLAMINE
REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR 4-(2,4-DIMETHYL-THIAZOL-
REMARK 900 5-YL)-PYRIMIDIN-2-YLAMINE
REMARK 900 RELATED ID: 1PXK RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR N-[4-(2,4-DIMETHYL-
REMARK 900 THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'-
REMARK 900 HYDROXYIMINOFORMAMIDE
REMARK 900 RELATED ID: 1PXL RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR [4-(2,4-DIMETHYL-THIAZOL-
REMARK 900 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL-
REMARK 900 PHENYL)-AMINE
REMARK 900 RELATED ID: 1PXM RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR 3-[4-(2,4-DIMETHYL-
REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL
REMARK 900 RELATED ID: 1PXN RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR 4-[4-(4-METHYL-2-
REMARK 900 METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2-
REMARK 900 YLAMINO]-PHENOL
REMARK 900 RELATED ID: 1PXO RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR [4-(2-AMINO-4-METHYL-
REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO-
REMARK 900 PHENYL)-AMINE
REMARK 900 RELATED ID: 1PXP RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED
REMARK 900 WITH THEINHIBITOR N-[4-(2,4-DIMETHYL-
REMARK 900 THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-
REMARK 900 DIMETHYL-BENZENE-1,4-DIAMINE
REMARK 900 RELATED ID: 1PYE RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB
REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE
REMARK 900 PEPTIDE COMPLEX
REMARK 900 RELATED ID: 1R78 RELATED DB: PDB
REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE
REMARK 900 INHIBITOR
REMARK 900 RELATED ID: 1URC RELATED DB: PDB
REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG-
REMARK 900 ARG-LEU-ASN-(P-F-PHE)-NH2
REMARK 900 RELATED ID: 1URW RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B]
REMARK 900 PYRIDAZINE
REMARK 900 RELATED ID: 1V1K RELATED DB: PDB
REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6
REMARK 900 -BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
REMARK 900 RELATED ID: 1VYW RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
REMARK 900 RELATED ID: 1W0X RELATED DB: PDB
REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX
REMARK 900 WITH THE INHIBITOR OLOMOUCINE.
REMARK 900 RELATED ID: 1W8C RELATED DB: PDB
REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-
REMARK 900 8-ISOPROPYL-9H-PURIN-2-YLAMINE AND
REMARK 900 MONOMERIC CDK2
REMARK 900 RELATED ID: 1W98 RELATED DB: PDB
REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY
REMARK 900 CYCLIN E
REMARK 900 RELATED ID: 1WCC RELATED DB: PDB
REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY
REMARK 900 CRYSTALLOGRAPHY
REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED
REMARK 900 WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR
REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED
REMARK 900 WITH A PYRAZOLO[1,5-A]PYRIMIDINE INHIBITOR
REMARK 900 RELATED ID: 2B52 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)
REMARK 900 COMPLEXED WITH DPH-042562
REMARK 900 RELATED ID: 2B53 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)
REMARK 900 COMPLEXED WITH DIN-234325
REMARK 900 RELATED ID: 2B54 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)
REMARK 900 COMPLEXED WITH DIN-232305
REMARK 900 RELATED ID: 2B55 RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)
REMARK 900 COMPLEXED WITHINDENOPYRAXOLE DIN-101312
REMARK 900 RELATED ID: 2BHE RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN
REMARK 900 COMPLEX WITH THE INHIBITOR 5-BROMO-
REMARK 900 INDIRUBINE
REMARK 900 RELATED ID: 2BHH RELATED DB: PDB
REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN
REMARK 900 COMPLEX WITH THE INHIBITOR 4-
REMARK 900 HYDROXYPIPERINDINESULFONYL-INDIRUBINE
REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
REMARK 900 RELATED ID: 2BPM RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
REMARK 900 RELATED ID: 2BTR RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
REMARK 900 RELATED ID: 2BTS RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
REMARK 900 RELATED ID: 2C4G RELATED DB: PDB
REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
REMARK 900 RELATED ID: 2C5N RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE
REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG
REMARK 900 DESIGN
REMARK 900 RELATED ID: 2C5O RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE
REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG
REMARK 900 DESIGN
REMARK 900 RELATED ID: 2C5T RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE
REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG
REMARK 900 DESIGN
REMARK 900 RELATED ID: 2C5V RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE
REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG
REMARK 900 DESIGN
REMARK 900 RELATED ID: 2C5X RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE
REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG
REMARK 900 DESIGN
REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB
REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE
REMARK 900 AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG
REMARK 900 DESIGN
REMARK 900 RELATED ID: 2C68 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2
REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
REMARK 900 RELATED ID: 2C69 RELATED DB: PDB
REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2
REMARK 900 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
DBREF 2C5P A 1 298 UNP P24941 CDK2_HUMAN 1 298
DBREF 2C5P B 173 432 UNP P20248 CCNA2_HUMAN 173 432
DBREF 2C5P C 1 298 UNP P24941 CDK2_HUMAN 1 298
DBREF 2C5P D 173 432 UNP P20248 CCNA2_HUMAN 173 432
SEQRES 1 A 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY
SEQRES 2 A 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR
SEQRES 3 A 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR
SEQRES 4 A 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE
SEQRES 5 A 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS
SEQRES 6 A 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU
SEQRES 7 A 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET
SEQRES 8 A 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE
SEQRES 9 A 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE
SEQRES 10 A 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO
SEQRES 11 A 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU
SEQRES 12 A 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL
SEQRES 13 A 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG
SEQRES 14 A 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR
SEQRES 15 A 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU
SEQRES 16 A 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU
SEQRES 17 A 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR
SEQRES 18 A 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO
SEQRES 19 A 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP
SEQRES 20 A 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG
SEQRES 21 A 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS
SEQRES 22 A 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE
SEQRES 23 A 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU
SEQRES 1 B 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR
SEQRES 2 B 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY
SEQRES 3 B 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG
SEQRES 4 B 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU
SEQRES 5 B 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN
SEQRES 6 B 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG
SEQRES 7 B 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU
SEQRES 8 B 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA
SEQRES 9 B 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS
SEQRES 10 B 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU
SEQRES 11 B 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU
SEQRES 12 B 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS
SEQRES 13 B 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU
SEQRES 14 B 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL
SEQRES 15 B 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL
SEQRES 16 B 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR
SEQRES 17 B 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP
SEQRES 18 B 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN
SEQRES 19 B 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS
SEQRES 20 B 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU
SEQRES 1 C 298 MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU GLY
SEQRES 2 C 298 THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU THR
SEQRES 3 C 298 GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP THR
SEQRES 4 C 298 GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU ILE
SEQRES 5 C 298 SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL LYS
SEQRES 6 C 298 LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR LEU
SEQRES 7 C 298 VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE MET
SEQRES 8 C 298 ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU ILE
SEQRES 9 C 298 LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA PHE
SEQRES 10 C 298 CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS PRO
SEQRES 11 C 298 GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS LEU
SEQRES 12 C 298 ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO VAL
SEQRES 13 C 298 ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR ARG
SEQRES 14 C 298 ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER THR
SEQRES 15 C 298 ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA GLU
SEQRES 16 C 298 MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER GLU
SEQRES 17 C 298 ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY THR
SEQRES 18 C 298 PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET PRO
SEQRES 19 C 298 ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN ASP
SEQRES 20 C 298 PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY ARG
SEQRES 21 C 298 SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN LYS
SEQRES 22 C 298 ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE PHE
SEQRES 23 C 298 GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU
SEQRES 1 D 260 ASN GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR
SEQRES 2 D 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY
SEQRES 3 D 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG
SEQRES 4 D 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU
SEQRES 5 D 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN
SEQRES 6 D 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG
SEQRES 7 D 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU
SEQRES 8 D 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA
SEQRES 9 D 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS
SEQRES 10 D 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU
SEQRES 11 D 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU
SEQRES 12 D 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS
SEQRES 13 D 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU
SEQRES 14 D 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL
SEQRES 15 D 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL
SEQRES 16 D 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR
SEQRES 17 D 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP
SEQRES 18 D 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN
SEQRES 19 D 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS
SEQRES 20 D 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU
HET CK7 A1297 23
HET CK7 C1298 69
HETNAM CK7 [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-
HETNAM 2 CK7 2-YL]-(3-NITRO-PHENYL)-AMINE
FORMUL 5 CK7 2(C14 H12 N6 O2 S)
FORMUL 7 HOH *655(H2 O1)
HELIX 1 1 PRO A 45 LEU A 58 1 14
HELIX 2 2 LEU A 87 SER A 94 1 8
HELIX 3 3 PRO A 100 HIS A 121 1 22
HELIX 4 4 LYS A 129 GLN A 131 5 3
HELIX 5 5 ALA A 170 LEU A 175 1 6
HELIX 6 6 THR A 182 ARG A 199 1 18
HELIX 7 7 SER A 207 GLY A 220 1 14
HELIX 8 8 GLY A 229 MET A 233 5 5
HELIX 9 9 ASP A 247 VAL A 252 1 6
HELIX 10 10 ASP A 256 LEU A 267 1 12
HELIX 11 11 SER A 276 LEU A 281 1 6
HELIX 12 12 ALA A 282 GLN A 287 5 6
HELIX 13 13 TYR B 178 CYS B 193 1 16
HELIX 14 14 GLY B 198 GLN B 203 5 6
HELIX 15 15 THR B 207 TYR B 225 1 19
HELIX 16 16 GLN B 228 MET B 246 1 19
HELIX 17 17 LYS B 252 GLU B 269 1 18
HELIX 18 18 GLU B 274 ILE B 281 1 8
HELIX 19 19 THR B 287 THR B 303 1 17
HELIX 20 20 THR B 310 PHE B 319 1 10
HELIX 21 21 LEU B 320 GLN B 322 5 3
HELIX 22 22 ASN B 326 SER B 340 1 15
HELIX 23 23 ASP B 343 LEU B 348 1 6
HELIX 24 24 LEU B 351 GLY B 369 1 19
HELIX 25 25 PRO B 373 GLY B 381 1 9
HELIX 26 26 THR B 383 ALA B 401 1 19
HELIX 27 27 PRO B 402 HIS B 404 5 3
HELIX 28 28 GLN B 407 TYR B 413 1 7
HELIX 29 29 LYS B 414 HIS B 419 5 6
HELIX 30 30 GLY B 420 LEU B 424 5 5
HELIX 31 31 PRO C 45 LYS C 56 1 12
HELIX 32 32 LEU C 87 ALA C 93 1 7
HELIX 33 33 PRO C 100 HIS C 121 1 22
HELIX 34 34 ASP C 145 ALA C 149 5 5
HELIX 35 35 ALA C 170 LEU C 175 1 6
HELIX 36 36 THR C 182 ARG C 199 1 18
HELIX 37 37 SER C 207 GLY C 220 1 14
HELIX 38 38 GLY C 229 MET C 233 5 5
HELIX 39 39 ASP C 247 VAL C 251 5 5
HELIX 40 40 ASP C 256 LEU C 267 1 12
HELIX 41 41 SER C 276 ALA C 282 1 7
HELIX 42 42 HIS C 283 VAL C 289 5 7
HELIX 43 43 TYR D 178 CYS D 193 1 16
HELIX 44 44 GLY D 198 GLN D 203 5 6
HELIX 45 45 THR D 207 TYR D 225 1 19
HELIX 46 46 GLN D 228 MET D 246 1 19
HELIX 47 47 LEU D 249 GLU D 269 1 21
HELIX 48 48 GLU D 274 ILE D 281 1 8
HELIX 49 49 THR D 287 LEU D 302 1 16
HELIX 50 50 THR D 310 PHE D 319 1 10
HELIX 51 51 LEU D 320 GLN D 322 5 3
HELIX 52 52 ASN D 326 ASP D 343 1 18
HELIX 53 53 ASP D 343 LEU D 348 1 6
HELIX 54 54 LEU D 351 THR D 368 1 18
HELIX 55 55 PRO D 373 GLY D 381 1 9
HELIX 56 56 THR D 383 ALA D 401 1 19
HELIX 57 57 PRO D 402 HIS D 404 5 3
HELIX 58 58 GLN D 407 TYR D 413 1 7
HELIX 59 59 LYS D 414 HIS D 419 5 6
HELIX 60 60 GLY D 420 LEU D 424 5 5
SHEET 1 AA 5 PHE A 4 GLY A 13 0
SHEET 2 AA 5 GLY A 16 ASN A 23 -1 O GLY A 16 N GLY A 13
SHEET 3 AA 5 VAL A 29 ILE A 35 -1 O VAL A 30 N ALA A 21
SHEET 4 AA 5 LEU A 76 GLU A 81 -1 O LEU A 76 N ILE A 35
SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79
SHEET 1 AB 3 GLN A 85 ASP A 86 0
SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85
SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134
SHEET 1 AC 2 VAL A 123 LEU A 124 0
SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124
SHEET 1 CA 5 PHE C 4 GLU C 12 0
SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10
SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21
SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35
SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79
SHEET 1 CB 3 GLN C 85 ASP C 86 0
SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85
SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134
SHEET 1 CC 2 VAL C 123 LEU C 124 0
SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124
CISPEP 1 GLN B 323 PRO B 324 0 -15.65
CISPEP 2 GLN D 323 PRO D 324 0 -3.13
SITE 1 AC1 13 ILE A 10 GLY A 13 ALA A 31 PHE A 80
SITE 2 AC1 13 GLU A 81 LEU A 83 HIS A 84 GLN A 85
SITE 3 AC1 13 ASP A 86 LYS A 89 LEU A 134 ASP A 145
SITE 4 AC1 13 HOH A2073
SITE 1 AC2 16 ILE C 10 GLY C 11 GLY C 13 VAL C 18
SITE 2 AC2 16 ALA C 31 LYS C 33 PHE C 80 GLU C 81
SITE 3 AC2 16 LEU C 83 HIS C 84 GLN C 85 ASP C 86
SITE 4 AC2 16 LEU C 134 ASP C 145 HOH C2033 HOH C2163
CRYST1 74.523 113.844 158.462 90.00 90.00 90.00 P 21 21 21 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.013419 0.000000 0.000000 0.00000
SCALE2 0.000000 0.008784 0.000000 0.00000
SCALE3 0.000000 0.000000 0.006311 0.00000